Alzheimer's Disease
Conditions
Brief summary
The goal of the study is to see what happens to levels of MK-1708 a person's body over time. Researchers will compare what happens to MK-1708 in the body when it is given with or without a medicine called itraconazole.
Interventions
DRUGMK-1708
Oral administration
DRUGItraconazole
Oral administration
Sponsors
Merck Sharp & Dohme LLC
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
The key inclusion criteria include but are not limited to the following: * Is in good health before randomization * Has a body mass index (BMI) ≥18.5 and ≤32 kg/m\^2, inclusive
Exclusion criteria
The key
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of MK-1708 | Predose and at designated timepoints up to approximately 2 weeks postdose | Blood samples will be collected to determine the AUC0-inf of MK-1708. |
| Number of Participants Who Experience an Adverse Event (AE) | Up to approximately 11 weeks | An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported. |
| Number of Participants Who Discontinue Study Due to an AE | Up to approximately 11 weeks | An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study due to an AE will be reported. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Plasma Concentration at 24 Hours (C24) of MK-1708 | Predose and at designated timepoints up to 24 hours postdose | Blood samples will be collected to determine the C24 of MK-1708. |
| Apparent Clearance (CL/F) of MK-1708 | Predose and at designated timepoints up to approximately 2 weeks postdose | Blood samples will be collected to determine the CL/F of MK-1708. |
| Area Under the Concentration-Time Curve from Time 0 to Last Quantifiable Concentration (AUC0-Last) of MK-1708 | Predose and at designated timepoints up to approximately 2 weeks postdose | Blood samples will be collected to determine the AUC0-last of MK-1708. |
| Apparent Terminal Half-life (t1/2) of MK-1708 | Predose and at designated timepoints up to approximately 2 weeks postdose | Blood samples will be collected to determine the t1/2 of MK-1708. |
| Apparent Volume of Distribution During Terminal Phase (Vz/F) of MK-1708 | Predose and at designated timepoints up to approximately 2 weeks postdose | Blood samples will be collected to determine the Vz/F of MK-1708. |
| Maximum Plasma Concentration (Cmax) of MK-1708 | Predose and at designated timepoints up to approximately 2 weeks postdose | Blood samples will be collected to determine the Cmax of MK-1708. |
| Time to Maximum Plasma Concentration (Tmax) of MK-1708 | Predose and at designated timepoints up to approximately 2 weeks postdose | Blood samples will be collected to determine the Tmax of MK-1708. |
Countries
United States
Outcome results
None listed